Neonatal hepatitis B vaccination protects mature adults from occult virus infection
Ruijun Wang # 1 , Chang Liu # 1 , Taoyang Chen # 2 , Yuting Wang 1 , Chunsun Fan 2 , Lingling Lu 2 , Fengmin Lu 3 , Chunfeng Qu 4
Affiliations
Affiliations
1
State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuan South Lane, Beijing, 100021, People's Republic of China.
2
Jiangsu, Qidong Liver Cancer Institute & Qidong People's Hospital, Qidong, 226200, People's Republic of China.
3
State Key Laboratory of Natural and Biomimetic Drugs, Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, People's Republic of China.
4
State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuan South Lane, Beijing, 100021, People's Republic of China. [email protected].
#
Contributed equally.
PMID: 33751394 DOI: 10.1007/s12072-021-10156-z
Abstract
Background: Among elder children/young adults who received hepatitis B virus (HBV) vaccination during infancy, the serological status of HBsAg-negative and anti-HBc-positive [HBsAg(-)/anti-HBc(+)] was frequently reported, indicating potential occult HBV infection (OBI). It is required to define the long-term protection of neonatal vaccination against OBI in their mature adulthood.
Methods: Building upon the 1983-1990 established Qidong Hepatitis B Intervention Study, we sampled 10% of the 28-35-year-old participants, who remained in the cohort by 2012. Each participant was tested for serological markers of HBsAg, anti-HBs, HBeAg, anti-HBe and anti-HBc. HBV-DNA and relaxed circular DNA (rcDNA) were determined in some HBsAg(-)/anti-HBc(+) individuals.
Results: Totally, 3615 individuals from the neonatal vaccination group and 3100 individuals from the control group donated blood samples, respectively. In the vaccination group, the prevalence of HBsAg was 1.58% (57/3615), HBsAg(-)/anti-HBc(+) was 4.70% (170/3615), significantly lower than in the control group, which was 7.45% (231/3100) and 19.48% (640/3100) respectively (all p < 0.001). With aging, HBsAg(-)/anti-HBc(+) prevalence increased in the sampled participants from the control group (pfor trend < 0.001), but uncertain from the vaccination group. Of HBsAg(-)/anti-HBc(+), HBV-DNA was detected in 13.08% (17/130) from the vaccination group, and in 4.18% (12/287) from the control group. HBV rcDNA was detected in most sera that were tested positive for HBV-DNA.
Conclusions: OBI occurred in some vaccinated adults. However, neonatal HBV vaccination kept the effective protection against OBI in mature adults.
Keywords: Antibody against HBV core antigen; Antibody to hepatitis B surface antigen; HBV relaxed circular DNA; Hepatitis B vaccination; Hepatitis B virus; Long-term protection; Mature adults; Neonatal vaccination; Occult HBV infection; Serological survey. 作者: StephenW 时间: 2021-3-23 15:41